Summary
A group of 26 patients with the clinical diagnosis of Senile Dementia of Alzheimer’s type (SDAT) was randomly assigned in a double blind cross-over trial of pyritinol versus placebo. Psychiatric and neurological examination, psychometric testing and regional cerebral blood flow measurements were used to assess the effects of medication. Pyritinol had a beneficial effect on cognitive performance which was sustained during the long term follow up of one year.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cohen G (1979) Language and comprehension in old age. Cognitive Psychology 11: 412–429
Cohen G, Faulkner D (1981) Memory for discourse in old age. Discourse Processes 4: 253–265
Cooper AJ, Magnus RV (1980) A placebo-controlled study of pyritinol ( Encephabol) in dementia. Pharmatherapeutica 2: 317–323
Erzigkeit H (1986) Der Syndrom-Kurztest zur Erfassung von Aufmerksamkeitsund Gedächtnisstörungen. Vless, Vaterstetten
Greiner HE, Haase AF, Seyfried CA (1988) Biochemical models for the study of the mechanism of action of an encephalotropic drug. In: Kanowski S, Ladurner G (eds) Dementielle Erkrankungen im Alter. Pathogenetische Modelle und Therapeutische Wirklichkeit. Thieme, Stuttgart, S 45–51
Hamouz W (1977) The use of pyritinol in patients with moderate to severe organic psychosyndrome. Pharmatherapeutica 1: 398–403
Herrmann WM, Kern U, Rohmel J (1986) The effects of pyritinol on functional deficits of patients with organic mental disorders. Pharmacopsychiatry 19: 378–385
Hoyer S, Oesterreich K, Stoll KD (1977) Effects of pyritinol-HC1 on blood flow and oxidative metabolism of the brain in patients with dementia. Drug Res 27: 671–674
Knezevic S, Mubrin Z, Risberg J, Vucinic G, Spilich G, Gubarev N, Wannenmacher W (1989) Pyritinol treatment of SDAT patients: evaluation by psychiatric and neurological examination, psychometric testing and rCBF measurements. Clin Psychopharmacol 4: 25–38
Martin KJ, Vyas S (1987) Increase in acetylcholine concentration in the brain of “old” rats following treatment with pyrithioxine ( Encephabol ). Br J Pharmacol 90: 561–569
Maximilian VA, Brawanski A (1988) Functional and vascular challenge procedures during noninvasive rCBF measurements. In: Knezevic S, Maximilian VA, Mubrin V, Prohovnik I, Wade J (eds) Handbook of regional cerebral blood flow. Lawrence Erlbaum Associates, Hove and London, pp 79–121
Mubrin Z, Knezevic S, Barac B, Poljakovic Z, Pudar-Klein M, Katic Z (1985a) Effect of mental activation on regional cerebral blood flow (rCBF) changes in patients with cerebrovascular disease. Neurologija (Zagreb) 31: 107–124
Mubrin Z, Knezevic S, Barac B, Gubarev N, Lazic M, Liscic R, Vidosic S (1985b) Distinct rCBF pattern during different types of short-term memory activation. In: Hartmann A, Hoyer S (eds) Cerebral blood flow and metabolism measurement. Springer, Berlin Heidelberg New York Tokyo, pp 81–87
Obrist WD, Thompson HK, Wang HS, Wilkinson WE (1975) Regional cerebral blood flow estimated by 133Xenon inhalation. Stroke 6: 245–256
Oswald WD, Oswald B, Grobe D, Lukaschek K, Sappa J, Fleischmann UM (1986) Recent approaches in the treatment and assessment of psychoorganic brain-syndromes. A double-blind study with pyritinol. In: Ramos GG, Herrmann WM, Otero E, Toledano A (eds) Advances in the field of cerebrovascular disease. Egrat, Madrid, pp 88–96
Pavlik A, Benesova O, Dlohozkova N (1987) Effects of nootropic drugs on brain cholinergic and dopaminergic transmission. Act Nery Sup 29: 62–65
Risberg J (1980) Regional cerebral blood flow measurements by 133Xe-inhalation: methodology and applications in neuropsychology and psychiatry. Brain Lang 9: 9–34
Risberg J (1985) Application of the nontraumatic xenon 133 method in neuropsychiatry. In: Hartmann A, Hoyer S (eds) Cerebral blood flow and metabolism measurement. Springer, Berlin Heidelberg New York Tokyo, pp 72–80
Risberg J, Ali Z, Wilson EM, Wills EL, Halsey JH Jr (1975) Regional cerebral blood flow by 133Xenon inhalation. Preliminary evaluation of an initial slope index in patients with unstable flow compartments. Stroke 6: 142–148
Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141: 1356–1365
Rosen WG, Terry RD, Fuld PA, et al (1980) Pathological verification of ischemic score in differentiation of demential. Ann Neurol 7: 486–488
Spilich GJ (1983) Life-span components of text processing: structural and procedural differences. Journal of Verbal Learning and Verbal Behavior 22: 231–244
Spilich GJ (1985) Discourse comprehension across the span of life. In: Charness N (ed) Aging and human performance. Wiley, New York, pp 143–190
Spilich GJ, Voss JF (1983) Contextual effects upon text memory for young, aged-normal, and aged memory-impaired individuals. Exp Aging Res 9: 45–49
Venn RD (1983) The Sandoz clinical assessment geriatric (SCAG) scale. Gerontology 29: 185–198
Wechsler D (1945) A standardized memory scale for clinical use. J Psychol 27: 91–94
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Wien
About this chapter
Cite this chapter
Knezevic, S., Mubrin, Z., Spilich, G., Vucinic, G., Wannenmacher, W. (1990). Long term treatment of SDAT patients with pyritinol. In: Maurer, K., Riederer, P., Beckmann, H. (eds) Alzheimer’s Disease. Epidemiology, Neuropathology, Neurochemistry, and Clinics. Key Topics in Brain Research. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3396-5_64
Download citation
DOI: https://doi.org/10.1007/978-3-7091-3396-5_64
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82197-8
Online ISBN: 978-3-7091-3396-5
eBook Packages: Springer Book Archive